BioSpace News Archive

Veru Inc. today announced that the Company will present at the following upcoming healthcare investor conferences. H.C. Wainwright 23rd Annual Global Investment Conference: September 13-15, 2021 Presentation available on September 13, 2021, at 7:00 AM ET

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon.

Jasper Therapeutics, Inc. today announced the initiation of a Phase 1/2 clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody

BioLargo, Inc. will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The conference is being held virtually on September 13-15, 2021.

Avinger, Inc. today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.C. Wainwright 23rd Annual Global Investment Conference.

Bringing an added level of confidence to the robust science that its assay offers, the bioMérieux, Inc. GENE-UP® NUTRAPLEX PRO™ multiplex pathogen detection assay has achieved the AOAC® Research Institute Performance Tested MethodsSM approval (PTM 082103).

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).

Royal Biologics, an ortho-biologics company focused on Autologous and Live Cellular solutions, has announced FDA 510K approval of their Maxx™-PRP concentration system.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in Citi’s 16th Annual BioPharma Virtual Conference 2021 investor conference.

Intrommune Therapeutics, Inc. announced the appointment of Stuart Loesch as its new Chief Commercial Officer.